Currently out of the existing stock ratings of Jack Meehan, 35 are a BUY (52.24%), 16 are a HOLD (23.88%), 16 are a SELL (23.88%).

Jack Meehan

Work Performance Price Targets & Ratings Chart

Analyst Jack Meehan, currently employed at BARCLAYS, carries an average stock price target met ratio of 97.59% that have a potential upside of 17.73% achieved within 260 days. Previously, Jack Meehan worked at STIFEL.

Jack Meehan’s has documented 159 price targets and ratings displayed on 17 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on A, Agilent Technologies at 15-Dec-2025.

Wall Street Analyst Jack Meehan

Analyst best performing recommendations are on INMD (INMODE LTD).
The best stock recommendation documented was for INMD (INMODE LTD) at 11/6/2019. The price target of $22.5 was fulfilled within 5 days with a profit of $3.07 (15.8%) receiving and performance score of 31.6.

Average potential price target upside

of $60.73 (9.21%) on MTD (METTLER-TOLEDO INTERNATIONAL).
of $57.66 (20.79%) on ILMN (ILLUMINA).
of $46.7 (17.5%) on BIO (BIO-RAD LABORATORIES).

HOLX Hologic MYGN Myriad Genetics PDD Pinduoduo A Agilent Technologies TMO Thermo Fisher Scientific DGX Quest Diagnostics ILMN Illumina QGEN Qiagen NV BIO Bio-Rad Laboratories INMD InMode Ltd IQV IQVIA Holdings MTD Mettler-Toledo International WAT Waters LH Laboratory of America Holdings BRKR Bruker GHDX Genomic Health ICLR ICON PLC

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score